Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 5Recruiting 5Active not recruiting 3Terminated 2Not yet recruiting 2Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Esophageal Squamous Cell Carcinoma 2Sarcopenia 1Osteoporosis 1Esophageal Neoplasms 1

Interventions

toripalimab 6Cisplatin 5130-nm albumin-bound paclitaxel 5Drug Therapy 4tislelizumab 3sintilimab 3camrelizumab 3Injections 3Immune Checkpoint Inhibitors 3Fluorouracil 3Carboplatin 3nedaplatin 2anlotinib 2Radiotherapy 2Paclitaxel 2Neoadjuvant Therapy 2Irinotecan 2Esophagectomy 2potassium oxonate 1pembrolizumab 1lenvatinib 1ivarmacitinib 1irinotecan sucrosofate 1Watchful Waiting 1Taxes 1TP protocol 1S 1 (combination) 1Radiotherapy, Intensity-Modulated 1Radiation 1Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Esophageal Squamous Cell Carcinoma × Esophagectomy × Clear all
NCT07244978 2026-04-24

Neoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
49 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07505186 2026-04-01

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
45 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡